BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 26
• 27
• 30

• Press Releases

  RadNet, Inc. to Present at the Sidoti & Company Small Cap 2024 Virtual Conference on Wednesday, September 18th

  September 18, 2024

   · 

  1 min read
• Press Releases

  Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer

  September 18, 2024

   · 

  6 min read
• Press Releases

  Charles River Comparative Study Reveals that Kytopen’s Flowfect Tx™ Platform Outperforms Conventional Electroporation Platforms

  September 18, 2024

   · 

  3 min read
• Press Releases

  Sensorion Reports 2024 First Half Results and Highlights Recent Updates

  September 18, 2024

   · 

  17 min read
• Press Releases

  Anokion Announces New Data from the Phase 1 MoveS-it Study Supporting ANK-700 as a Novel, Potential Disease Modifying Treatment for Relapsing-Remitting Multiple Sclerosis

  September 18, 2024

   · 

  2 min read
• Press Releases

  Clarivate Announces 15th Annual Pharmavision India Conference Agenda

  September 18, 2024

   · 

  3 min read
• Press Releases

  Promino Nutritional Sciences Inc. Begins Preclinical Trial to Demonstrate Effectiveness of Promino™ Patented IP for Retention of Muscle Mass in Cancer Patients Undergoing Aggressive Chemotherapy Treatment

  September 18, 2024

   · 

  5 min read
• Press Releases

  New Alzheon Peer-Reviewed Scientific Publication Describes Study Design and Baseline Characteristics from APOLLOE4 Phase 3 Trial of Oral ALZ-801/Valiltramiprosate in APOE4/4 Homozygous Individuals with Early Alzheimer’s Disease

  September 18, 2024

   · 

  10 min read
• Press Releases

  Biosyngen’s first-in-class CAR-T asset targeting solid tumors has entered pivotal phase II trial, Phase I trial data debut at ESMO 2024 Annual Congress

  September 18, 2024

   · 

  4 min read
• Press Releases

  New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis

  September 18, 2024

   · 

  18 min read